On October 22, local time, the French National Agency for the Safety of Medicines and Health Products (ANSM) issued a vaccination follow-up report stating that since June this year, myocarditis has been considered to be extremely rare after vaccination with Pfizer and Modena's new crown vaccine. Adverse reactions.
From the still limited data, among young men aged 18 to 29, the proportion of reported myocarditis after vaccination with Modena is higher.
Data show that from January 19 to October 14 this year, France has vaccinated more than 10 million doses of Modena vaccine, and a total of 106 cases of adverse reactions to myocarditis have been reported, of which 62 were vaccinators under 30 years of age.
In all cases of myocarditis, the ratio of male to female is about 5 to 1, and 79% of the cases occurred after completing the entire vaccination.
The French National Agency for the Safety of Medicines and Health Products therefore recommends that if the vaccinators of Modena's new crown vaccine develop symptoms of myocarditis such as shortness of breath, chest pain, palpitations or irregular heartbeats, they should seek immediate medical attention.
In early October, a number of Nordic countries took preventive measures due to the risk of myocarditis and suspended the vaccination of Modena for young people.
Affected by this, the French High Health Administration (HAS) also expressed a cautious attitude towards the vaccination of the Modena vaccine booster on October 15 and suggested that it wait for the evaluation opinions of the European Medicines Agency.
(Headquarters reporter Zou Heyi)